Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranaz acquires Bar Tech
Ranaz has acquired all outstanding shares of Bar Tech, which were held by four shareholders, in exchange for 738,673 common shares and 369,337 warrants. Each Warrant entitles its
Ranaz has acquired all outstanding shares of Bar Tech, which were held by four shareholders, in exchange for 738,673 common shares and 369,337 warrants. Each Warrant entitles its
Nucleonics plans to enroll a total of 15 patients infected with hepatitis B virus (HBV) with mild to moderate disease and no evidence of cirrhosis at three US
A consolidation of existing shares has taken place and additional shares will be issued as consideration for the merger. As a result of this merger, it is anticipated
One of these clinical trials did not meet its primary endpoint of demonstrating a statistically significant reduction in patients’s pain intensity levels over 48 hours compared to placebo,
This patent application represents a very significant move strategically for Solagran. It constitutes the first step towards changing the status of Bioeffective(r) A from a complementary medicine substance,
Alder plans to use the financing to advance its lead programs through human clinical trials and to continue to advance its proprietary Mab Xpress yeast antibody production technology.
These approvals follow positive opinions granted in September and October, respectively, by the Committee for Medicinal Products for Human Use for the European Medicines Agency. Based on analysis
The mission of the partnership is to advance knowledge in the field of proliferative and degenerative diseases through fundamental and applied biology research. The Ipsen Life Sciences Program
The agreement spans for two years and involves manufacturing of CellaVision’s analysis instruments of a worth of around SEK25 million annually. The new agreement will replace the previous
The patent will serve to enhance protection of the intellectual property underlying the company’s Prometa treatment program. This patent, the second allowance in the US, represents the securing